Biologics market research report

RITMIR039: Biologics – A Market Insight Report, July 2013
© RI Technologies - www.researchimpact.com Sample Page - 1
BIOLOGICS MARKET SIZE
Scope of the Study
This report on Biologics gives a market insight into product types including Monoclonal Antibodies, Blood &
Blood Products, Vaccines, Insulin and Other, for both human and animal consumption. Market projections
and estimates are illustrated by region and by type. The report serves as a guide to Biologics market,
covering more than 250 companies that are engaged in Biologics products and services. Major Contract
Research Organizations, Research Institutes and Universities serving the Animal Biologics industry are also
covered in the corporate directory section of this report. Information related to recent product releases,
product developments, partnerships, collaborations, and mergers and acquisitions is covered in the report.
Compilation of Worldwide Patents related to Biologic products is also provided. A global perspective is
presented along with regional analysis covering the regions of North America, Europe, Asia-Pacific, and Rest
of World with 116 exclusive graphically represented exhibits.
Biologics’ report is an ideal research tool providing strategic business intelligence to the corporate sector.
This report may help strategists, investors, laboratories, pharmaceutical companies, contract research
organizations, biotechnology companies and drug approval authorities in--
 Gauging Competitive Intelligence
 Identifying Key Growth Areas and Opportunities
 Understanding Geographic Relevance to Product
 Knowing Regional Market Sizes and Growth Opportunities and Restraints
 Keeping Tab on Emerging Technologies
 Equity Analysis
 Tapping New Markets
Analytics and data presented in this report pertain to several parameters such as –
 Global and Regional Market Sizes, Market Shares, Market Trends
 Product (Global and Regional) Market Sizes, Market Shares, Market Trends
 Technology Trends
 Corporate Intelligence
 Key Companies by Sales, Brands, Products
 Consumer Behavioral Patterns
 Other Strategic Business Affecting Data

Research Methodology
RI Technologies publishes business intelligence reports by going through a cycle of diligent research and
analysis activity. Research is done using both online and offline resources. The study outline of this report is
sketched on the following lines – global market analysis, regional market analysis, product segmentation,
global and regional market analysis by product segment, market trends, M&A, R&D, competitive landscape,
technology trends, and other key drivers. Current data helps in analyzing the future of the industry and is
also helpful for doing market evaluations, and estimating the market size for the future.
This report is uniquely researched and the methodology includes:
 Need and Scope of Study
 Product Definitions
 Segmental Analysis
 Regional Analysis
 Exclusive Data Analytics
 Corporate Intelligence
 Feedback
Right from concept to final compilation of this report, both primary and secondary research methods are
applied. We have provided exclusive feedback forms/pre-release questionnaires for this report to use the
information for authentication of our own findings. Secondary research includes government publications,
investment research reports, web based surveys, website information of both companies and markets, and
other offline resources such as print publications and CDs.
Our compilation of easy to navigate PDF reports are essential value addition resources for leading and
growing companies.

CHAPTER II - REPORT SYNOPSIS
Biologics
Biologics is a preparation like a drug, a vaccine or an antitoxin which is produced from living organisms or
products obtained from them. These are used as diagnostic, preventive or an agent for treatment.
The official definition of biologics or biological products according to FDA is “any virus, toxin, antitoxin,
therapeutic serum or analogous product that can be used to prevent, treat or cure diseases or injuries of
man”.
Biopharmaceuticals: This is a pharmaceutical that has been obtained from biological sources particularly
those manufactured by using biotechnology.
Biosimilars: Biosimilars are also called as follow -on biologics. These are biologic medical products wherein
the active drug substance is synthesized by a living organism or derived from a living organism by using
either recombinant DNA or controlled gene expression procedure.
Monoclonal Antibodies: Monoclonal Antibodies (mAb or moAb) are essentially monospecific antibodies.
These are the same as they are made by exactly same immune cells that are clones of a unique parent cell.
As opposed to this, polyclonal antibodies are made from several different immune cells. Monoclonal
antibodies have monovalent affinity as these bind to the same epitope.
Segmentation of Biologics Market
Exhibit 1. Segmentation of Global Biologics Market by Type and Species
Type Species
Monoclonal Antibodies Human
Blood & Blood Products Animal
Vaccines
Insulin
Other
* Growth Hormones/Factors
© RIT, 2013

Global Market Analysis
Global Biologics market is projected to reach about US$ XX.XX billion by 2020 from an estimated US$ XX.XX
billion in 2012, growing at a very high compounded annual growth rate (CAGR) of XX.XX % during the
analysis period 2005-2020.
Exhibit 2. Biologics – Global Value Market Estimations and Predictions (2005-2020) in US$ Million
Year Value
2005 XX.XX
2006 XX.XX
2007 XX.XX
2008 XX.XX
2009 XX.XX
2010 XX.XX
2011 XX.XX
2012 XX.XX
2013 XX.XX
2014 XX.XX
2015 XX.XX
2016 XX.XX
2017 XX.XX
2018 XX.XX
2019 XX.XX
2020 XX.XX
CAGR % XX.XX
© RIT Figures, 2013
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020
US$ Million

Exhibit 3. List of Major Global Biologics Companies
S. No Company Country Website
1 Abbott Laboratories USA www.abbott.com
2 Novartis Animal Health Switzerland www.ah.novartis.com
3 Sanofi SA France www.sanofi.com
4 Zoetis Animal Health USA www.zoetis.com
More…
© RIT, 2013

III. MARKET DYNAMICS
North American Biologics Market
United States is estimated as the largest market for Biologics in North America, with an estimated share of
XX.XX % in 2012. In terms of value, United States is projected to reach US$ XX.XX billion by 2020, from an
estimated US$ XX.XX billion in 2012. Canada is projected to represent the fastest growing market for
Biologics in North American region during 2005-2020 with a CAGR of XX.XX %.
Exhibit 4. Biologics - North American Value Market Estimations and Predictions (2005-2020) by Countries
for United States and Canada in US$ Billion
Year/Country United States Canada Total
2005 XX.XX XX.XX XX.XX
CAGR% XX.XX XX.XX XX.XX
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020
US$ Billion
United States Canada

Exhibit 5. Biologics - North American Value Market Shares (2010, 2015 & 2020) by Country for United
States and Canada
Year/Country United States Canada Total
CAGR% XX.XX XX.XX XX.XX
US Biologics Market
United States Biologics market is projected to grow at a CAGR of XX.XX % during 2005-2020, to almost
reach US$ XX.XX billion by 2020, from an estimated market value of US$ XX.XX billion in 2012.
Canadian Biologics Market
Canadian Biologics market is projected to grow at a CAGR of XX.XX % during 2005-2020 to reach US$ XX.XX
billion by 2020, from an estimated market value of US$ XX.XX billion in 2012.

Biologics - Analysis by Type
Global market for Blood & Blood Products is estimated as the largest Biologics segment, valued at US$
XX.XX billion in 2012, accounting for more than half of the market. Blood & Blood Products market is
expected to reach about US$ XX.XX billion by 2020, and fastest CAGR of XX.XX %, followed by Monoclonal
Antibodies with a CAGR of XX.XX % during the above analysis period 2005-2020.
Exhibit 6. Biologics – Global Value Market Estimations and Predictions (2005-2020) by Type for
Monoclonal Antibodies, Blood & Blood Products, Vaccines, Insulin and Other in US$ Billion
Year/Region Monoclonal Antibodies Blood & Blood Products Vaccines Insulin Other Total
2005 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX
CAGR% XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020
US$ Billion
MonoclonalAntibodies Blood & Blood Products Vaccines Insulin Other

Exhibit 7. Biologics– Global Value Market Shares (2010, 2015 &2020) by Type for Monoclonal Antibodies,
Blood & Blood Products, Vaccines, Insulin and Other
Year/Region Monoclonal Antibodies Blood & Blood Products Vaccines Insulin Other Total
CAGR% XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX

IV. PRODUCT/TECHNOLOGY RESEARCH
Biologics – Introduction
There have been a lot of developments in biotechnology and medicines and this has led to entry and
increase of biologics. Chemical drugs are simple, small molecule compounds. These have been developed
by chemists and produced in the form of pills. Examples include aspirin, Ibuprofen etc. Biologics are large,
complex molecules developed by bioengineered bacteria and other living organisms. These have a great
potential for the therapy of cancer, autoimmune diseases and other critical diseases. Drug producers have
been promised patent protection and are tempted by the strong market rates so they have ventured into
this area. They are working to develop new biologics to be used in several therapeutic areas.
Biologics development has not reached its full potential as it is expensive and the second important factor
is the safety issue. Therapy with biologics is costly and the total costs may go up to hundreds of thousands
of dollars annually. The second important concern is safety. This is due to the fact that biologics are larger
and more complex than small-molecule drugs. Hence, the manufacture, quality control and quality
assurance is a big problem. Minute changes in a biologic’s production can alter its chemical properties and
the way it affects individuals.
Competition from generic versions of brand name biologics termed as “follow-on biologics”, would take
care of the expenses by providing inexpensive alternatives and also offer growth for generic biologic
producers to continue research and development. As such there is no legislative framework to look after
approval of generic biologics. As per the Public Health Safety Act (“PHSA”) generic biologics too have to be
approved similar to the reference biologics.
A biologic medicine is a big molecule which is obtained from living cells and used for therapy, diagnosis or
prevention of disease. The biologic medicines are therapeutic proteins, DNA vaccines, monoclonal
antibodies and fusion proteins. Biologic medicines are about 200 to 1000 times larger than small molecule
drugs and are structurally complex as well. These are very sensitive, so it is difficult to manufacture and
categorize these. Due to the properties of size and sensitivity, the biologic medicines are mostly injected
into the body of the patient.
Exhibit 8. List of Best Selling Biologics
Biologic Company Description Patent Expiry Sales (2011)
Enbrel Amgen TNF inhibitor 2028 US$ 7.4 billion
Novolog Novo Nordisk Insulin Analog 2014 US$ 2.4 billion
Lantus Sanofi SA Insulin Analog 2015 US$ 5.4 billion
Neulasta Amgen G-CSF 2015 US$ 5.2 billion
Humira Abbott ---- ----- ----
Rituxan Genentech ---- ----- ----
More….
© RIT, 2013

About RI Technologies
RI Technologies is a premier source of market research on the Biotechnology & Healthcare sector. We
emphasize on factual insights and forecasts with maximum global coverage. RI Technologies is constantly
monitoring the biotechnology & Healthcare industry, tracking market trends, and forecasting industry
based on specialized analysis. The life sciences sector is an ever growing marketplace with emerging
technologies in areas of discovery, design and development.
Research – As Good as the Methodology is!
 Gauging Competitive Intelligence
 Identifying Key Growth Areas and Opportunities
 Understanding Geographic Relevance to Product
 Knowing Regional Market Sizes and Growth Opportunities and Restraints
 Keeping Tab on Emerging Technologies
 Equity Analysis
 Tapping New Markets
© COPYRIGHT
The copyright and publication rights to all RI Technologies' reports and other products are the property of
the company. Plagiarism of any kind accounts to violation of copyright laws. Any type of reproduction of
the material without express permission is not allowed. The buyer, under no circumstances, shall license,
resell or repackage, or sell data without prior permission of the company.
DISCLAIMER
RI Technologies sells content in good faith. The company is not liable to the buyer for any implications
arising out of the usage of data for any particular purpose. The company makes no representations or
warranties for the accuracy or completeness of the data. While extreme caution and effort is practiced for
data compilation and presentation, the company does not accept any responsibility for findings in the study
which are a cumulative effort of primary and secondary research resources. The studies do not endorse or
promote any product or company. RI Technologies, its affiliates, partners, distributors, and contractors are
not liable for inaccuracies or incompleteness of the reports. User discretion is recommended for the usage
of the data.

Biologics market research report

Recomendados

Recomendados

Más contenido relacionado

Más de Research Impact

Más de Research Impact (11)

Último

Último (20)

Biologics market research report